Abstract
The current clinical practice advocates dual antiplatelet therapy (DAPT) for a year after ST segment elevation myocardial infarction (STEMI), primarily owing to persistent thrombotic risk. The novel COBRA PzF coronary stent was developed to reduce stent thrombosis risk. The primary goal of the current research was to compare the efficacy and safety of the novel nanocoated PzF stenting with one-month DAPT (dual anti-platelet therapy) against 12-month DAPT after the current drug- eluting stent (DES) in STEMI patients and single-vessel coronary artery disease (CAD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
